title: Prevention of postpartum psychosis and mania in women at high risk.
abstract: OBJECTIVE
  Women with a history of bipolar disorder or postpartum psychosis are at extremely high risk of relapse postpartum. Although lithium prophylaxis has demonstrated efficacy in reducing postpartum relapse, the timing of prophylaxis remains controversial given the balance of risks and benefits for the mother and fetus. The authors compared lithium use during pregnancy to its initiation postpartum in women at high risk for postpartum psychosis.
  
  
  METHODS
  Between 2003 and 2010, 70 pregnant women at high risk for postpartum psychosis were referred to the authors' psychiatric outpatient clinic. Women who were initially medication free were advised to start lithium prophylaxis immediately postpartum. Women already taking maintenance lithium during pregnancy were advised to continue treatment.
  
  
  RESULTS
  All women with a history of psychosis limited to the postpartum period (N=29) remained stable throughout pregnancy despite being medication free. Of the women with bipolar disorder (N=41), 24.4% relapsed during pregnancy, despite prophylaxis use by the majority throughout pregnancy. The postpartum relapse rate was highest in women with bipolar disorder who experienced mood episodes during pregnancy (60.0%). In contrast, none of the 20 women with a history of postpartum psychosis only who used postpartum prophylaxis relapsed, compared to 44.4% of patients with postpartum psychosis only who declined prophylaxis.
  
  
  CONCLUSIONS
  The authors recommend initiating prophylactic treatment immediately postpartum in women with a history of psychosis limited to the postpartum period, to avoid in utero fetal exposure to medication. Patients with bipolar disorder require continuous prophylaxis throughout pregnancy and the postpartum period to reduce peripartum relapse risk.
authors.affiliation: Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands. v.bergink@erasmusmc.nl
authors.forename: Veerle
authors.initials: V
authors.lastname: Bergink
authors.forename: Paul F
authors.initials: PF
authors.lastname: Bouvy
authors.forename: Jeroen S P
authors.initials: JS
authors.lastname: Vervoort
authors.forename: Kathelijne M
authors.initials: KM
authors.lastname: Koorengevel
authors.forename: Eric A P
authors.initials: EA
authors.lastname: Steegers
authors.forename: Steven A
authors.initials: SA
authors.lastname: Kushner
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000517:prevention & control*; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000627:therapeutic use; D049590:Postpartum Period / Q000523:psychology*; D011247:Pregnancy; D011618:Psychotic Disorders / Q000517:prevention & control*; D012307:Risk Factors; D055502:Secondary Prevention
chemical_list: D018692:Antimanic Agents; D018020:Lithium Compounds